Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on November 24, 2004
J Am Soc Nephrol 16: 46-51, 2005
© 2005 American Society of Nephrology
doi: 10.1681/ASN.2004080660

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2004080660v1
16/1/46    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tao, Y.
Right arrow Articles by Edelstein, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tao, Y.
Right arrow Articles by Edelstein, C. L.

Fast Track

Rapamycin Markedly Slows Disease Progression in a Rat Model of Polycystic Kidney Disease

Yunxia Tao, Jun Kim, Robert W. Schrier and Charles L. Edelstein

Division of Renal Diseases and Hypertension, University of Colorado Health Sciences Center, Denver, Colorado

Address correspondence to: Dr. Charles L. Edelstein, Division of Renal Diseases and Hypertension, University of Colorado School of Medicine, Box C281, 4200 E. 9th Avenue, Denver, CO 80262. Phone: 303-315-8764; Fax: 303-315-4852; E-mail: Charles.edelstein{at}uchsc.edu

Increased tubular epithelial cell proliferation is a prerequisite for cyst formation and expansion in polycystic kidney disease (PKD). Rapamycin is a potent antiproliferative agent. The aim of the present study was to determine the effect of rapamycin on tubular cell proliferation, cyst formation, and renal failure in the Han:SPRD rat model of PKD. Heterozygous (Cy/+) and littermate control (+/+) male rats were weaned at 3 wk of age and then treated with rapamycin 0.2 mg/kg per d intraperitoneally or vehicle (ethanol) for 5 wk. Vehicle-treated Cy/+ rats had a more than doubling of kidney size compared with +/+ rats. Rapamycin reduced the kidney enlargement by 65%. Rapamycin significantly reduced the cyst volume density in Cy/+ rats by >40%. Blood urea nitrogen was 59% increased in vehicle-treated Cy/+ rats compared with +/+ rats. Rapamycin reduced the blood urea nitrogen to normal in Cy/+ rats. The number of proliferating cell nuclear antigen (PCNA)-positive cells per noncystic tubule was eightfold increased in vehicle-treated Cy/+ compared with +/+ rats. Rapamycin significantly reduced the number of PCNA-positive cells in noncystic tubules of Cy/+ rats. In addition, the number of PCNA-positive cells per cyst in Cy/+ rats was significantly reduced by rapamycin. In summary, in a rat model of PKD, rapamycin treatment (1) decreases proliferation in cystic and noncystic tubules, (2) markedly inhibits renal enlargement and cystogenesis, and (3) prevents the loss of kidney function.




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
L. Battini, S. Macip, E. Fedorova, S. Dikman, S. Somlo, C. Montagna, and G. L. Gusella
Loss of polycystin-1 causes centrosome amplification and genomic instability
Hum. Mol. Genet., September 15, 2008; 17(18): 2819 - 2833.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. J. Leuenroth, N. Bencivenga, P. Igarashi, S. Somlo, and C. M. Crews
Triptolide Reduces Cystogenesis in a Model of ADPKD
J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1659 - 1662.
[Abstract] [Full Text] [PDF]


Home page
CJASNHome page
C. L. Edelstein
Mammalian Target of Rapamycin and Caspase Inhibitors in Polycystic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1219 - 1226.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
Y. Tao, I. Zafar, J. Kim, R. W. Schrier, and C. L. Edelstein
Caspase-3 Gene Deletion Prolongs Survival in Polycystic Kidney Disease
J. Am. Soc. Nephrol., April 1, 2008; 19(4): 749 - 755.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
C. C. Berthier, P. R. Wahl, M. L. Hir, H.-P. Marti, U. Wagner, H. Rehrauer, R. P. Wuthrich, and A. L. Serra
Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease
Nephrol. Dial. Transplant., March 1, 2008; 23(3): 880 - 889.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
Q. Qian, H. Du, B. F. King, S. Kumar, P. G. Dean, F. G. Cosio, and V. E. Torres
Sirolimus Reduces Polycystic Liver Volume in ADPKD Patients
J. Am. Soc. Nephrol., March 1, 2008; 19(3): 631 - 638.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. Kramer, Y. Wang-Rosenke, V. Scholl, E. Binder, T. Loof, D. Khadzhynov, H. Kawachi, F. Shimizu, F. Diekmann, K. Budde, et al.
Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat
Am J Physiol Renal Physiol, February 1, 2008; 294(2): F440 - F449.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
M. Baba, M. Furihata, S.-B. Hong, L. Tessarollo, D. C. Haines, E. Southon, V. Patel, P. Igarashi, W. G. Alvord, R. Leighty, et al.
Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys
J Natl Cancer Inst, January 16, 2008; 100(2): 140 - 154.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
O. Ibraghimov-Beskrovnaya
Molecular pathogenesis of ADPKD and development of targeted therapeutic options
Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3367 - 3370.
[Full Text] [PDF]


Home page
Am. J. Pathol.Home page
K. Sataranatarajan, M. M. Mariappan, M. J. Lee, D. Feliers, G. G. Choudhury, J. L. Barnes, and B. S. Kasinath
Regulation of Elongation Phase of mRNA Translation in Diabetic Nephropathy: Amelioration by Rapamycin
Am. J. Pathol., December 1, 2007; 171(6): 1733 - 1742.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
T. Weimbs
Polycystic kidney disease and renal injury repair: common pathways, fluid flow, and the function of polycystin-1
Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1423 - F1432.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. W. Kuehn and G. Walz
Prime time for polycystic kidney disease: does one shot of roscovitine bring the cure?
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2133 - 2135.
[Full Text] [PDF]


Home page
CJASNHome page
A. Schwarz, S. Vatandaslar, S. Merkel, and H. Haller
Renal Cell Carcinoma in Transplant Recipients with Acquired Cystic Kidney Disease
Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 750 - 756.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
C. R. Amura, K. S. Brodsky, R. Groff, V. H. Gattone, N. F. Voelkel, and R. B. Doctor
VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/-) mice
Am J Physiol Cell Physiol, July 1, 2007; 293(1): C419 - C428.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. B. Chapman
Autosomal Dominant Polycystic Kidney Disease: Time for a Change?
J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1399 - 1407.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. J. Leuenroth, D. Okuhara, J. D. Shotwell, G. S. Markowitz, Z. Yu, S. Somlo, and C. M. Crews
Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease
PNAS, March 13, 2007; 104(11): 4389 - 4394.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
W. M. Bernhardt, M. S. Wiesener, A. Weidemann, R. Schmitt, W. Weichert, P. Lechler, V. Campean, A. C. M. Ong, C. Willam, N. Gretz, et al.
Involvement of Hypoxia-Inducible Transcription Factors in Polycystic Kidney Disease
Am. J. Pathol., March 1, 2007; 170(3): 830 - 842.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. S. Kasinath, M. M. Mariappan, K. Sataranatarajan, M. J. Lee, and D. Feliers
mRNA Translation: Unexplored Territory in Renal Science
J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3281 - 3292.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Zhang, J. Li, L. H. Young, and M. J. Caplan
AMP-activated protein kinase regulates the assembly of epithelial tight junctions
PNAS, November 14, 2006; 103(46): 17272 - 17277.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
C. R Lawson, T. W Doulton, and G. A MacGregor
Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease
Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 139 - 145.
[Abstract] [PDF]


Home page
Nephrol Dial TransplantHome page
M. Y. Chang, E. Parker, S. Ibrahim, J. R. Shortland, M. E. Nahas, J. L. Haylor, and A. C. M. Ong
Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2078 - 2084.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
V. E. Torres
Water for ADPKD? Probably, Yes
J. Am. Soc. Nephrol., August 1, 2006; 17(8): 2089 - 2091.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
G. Walz
Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel?
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1752 - 1757.
[Full Text] [PDF]


Home page
NEJMHome page
J. J. Grantham, V. E. Torres, A. B. Chapman, L. M. Guay-Woodford, K. T. Bae, B. F. King Jr., L. H. Wetzel, D. A. Baumgarten, P. J. Kenney, P. C. Harris, et al.
Volume Progression in Polycystic Kidney Disease
N. Engl. J. Med., May 18, 2006; 354(20): 2122 - 2130.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
N. Lloberas, J. M. Cruzado, M. Franquesa, I. Herrero-Fresneda, J. Torras, G. Alperovich, I. Rama, A. Vidal, and J. M. Grinyo
Mammalian Target of Rapamycin Pathway Blockade Slows Progression of Diabetic Kidney Disease in Rats
J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1395 - 1404.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Shillingford, N. S. Murcia, C. H. Larson, S. H. Low, R. Hedgepeth, N. Brown, C. A. Flask, A. C. Novick, D. A. Goldfarb, A. Kramer-Zucker, et al.
From the Cover: The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease
PNAS, April 4, 2006; 103(14): 5466 - 5471.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
P. R. Wahl, A. L. Serra, M. Le Hir, K. D. Molle, M. N. Hall, and R. P. Wuthrich
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD)
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 598 - 604.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
R. G.B. Bonegio, R. Fuhro, Z. Wang, C. R. Valeri, C. Andry, D. J. Salant, and W. Lieberthal
Rapamycin Ameliorates Proteinuria-Associated Tubulointerstitial Inflammation and Fibrosis in Experimental Membranous Nephropathy
J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2063 - 2072.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Tao, J. Kim, S. Faubel, J. C. Wu, S. A. Falk, R. W. Schrier, and C. L. Edelstein
Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease
PNAS, May 10, 2005; 102(19): 6954 - 6959.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP